Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Esserman, Laura J., Berry, Donald A., Cheang, Maggie C. U., Yau, Christina, Perou, Charles M., Carey, Lisa, DeMichele, Angela, Gray, Joe W., Conway-Dorsey, Kathleen, Lenburg, Marc E., Buxton, Meredith B., Davis, Sarah E., van’t Veer, Laura J., Hudis, Clifford, Chin, Koei, Wolf, Denise, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debu, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Livasy, Chad, Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunni-Yi, Giri, Dilip, Au, Alfred, Hylton, Nola
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2011
Gaiak:
Clinical Trial
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3332388/
https://ncbi.nlm.nih.gov/pubmed/22198468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1895-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak